Avacta Group PLC Issue of Equity (1128I)
March 23 2015 - 3:01AM
UK Regulatory
TIDMAVCT
RNS Number : 1128I
Avacta Group PLC
23 March 2015
Press Release 23 March 2015
Avacta Group plc
("Avacta" or the "Group")
Issue of Equity
Avacta Group plc (AIM: AVCT), the global provider of proprietary
diagnostic tools, consumables and reagents for human and animal
healthcare, today announces that 150,000 Ordinary Shares of 0.1p
("new Ordinary Shares") have been issued by the Company pursuant to
the exercise of share options by employees.
Application will be made for the new Ordinary Shares to be
admitted to trading on AIM and dealings are expected to commence on
26 March 2015.
The total number of Ordinary Shares in issue following the above
issue will be 4,975,299,550 each with voting rights. No Ordinary
Shares are held in Treasury.
The above figure of 4,975,299,550 shares may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FSA's
Disclosure and Transparency Rules.
- Ends -
Enquiries:
Avacta Group plc Tel: +44 (0) 844
414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Tim Sykes, Chief Financial
Officer
Numis Securities Limited Tel: +44 (0) 207
260 1000
Michael Meade / Freddie Barnfield www.numiscorp.com
- Nominated Adviser
James Black - Corporate Broking
Walbrook PR Limited Tel: +44 (0) 20 7933 8780
or avacta@walbrookpr.com
Paul McManus Mob: +44 (0)7890 541 893
Lianne Cawthorne Mob: +44 (0)7584 391 303
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative
technologies, consumables and reagents for the life science
markets, from drug discovery to diagnostics. Avacta operates
through two divisions:
Avacta Animal Veterinary diagnostics reference
Health laboratory and diagnostic kit
www.avactaanimalhealth.com provider.
---------------------------- ---------------------------------------
Avacta Life Sciences Novel non-antibody affinity
www.avactalifesciences.com reagents called Affimers, with
a wide range of Life Science
applications in diagnostics,
drug and biomarker discover
and biotech research and development.
---------------------------- ---------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUUAVRVVAOUAR
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024